Categories: News

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 135832. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50895, or by accessing the investors section of the company’s website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Contact:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com

Website: www.championsoncology.com
Facebook: www.facebook.com/championsoncology/
LinkedIn: www.linkedin.com/company/champions-oncology-inc-/
Twitter: www.twitter.com/ChampionsOncol1
Instagram: www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on accesswire.com

View the original press release on accesswire.com

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

1 hour ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

4 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

7 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

10 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

10 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

10 hours ago